Ally Bridge Group NY LLC Buys New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Ally Bridge Group NY LLC purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 106,434 shares of the company’s stock, valued at approximately $2,320,000. Dianthus Therapeutics accounts for approximately 1.9% of Ally Bridge Group NY LLC’s holdings, making the stock its 25th largest holding. Ally Bridge Group NY LLC owned 0.36% of Dianthus Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DNTH. TCG Crossover Management LLC purchased a new stake in Dianthus Therapeutics in the 4th quarter valued at $32,735,000. Northern Trust Corp boosted its stake in shares of Dianthus Therapeutics by 21.2% during the fourth quarter. Northern Trust Corp now owns 245,523 shares of the company’s stock worth $5,352,000 after buying an additional 42,923 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of Dianthus Therapeutics during the fourth quarter worth about $3,924,000. Price T Rowe Associates Inc. MD increased its position in Dianthus Therapeutics by 21.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company’s stock valued at $207,000 after acquiring an additional 1,647 shares during the period. Finally, MetLife Investment Management LLC raised its stake in Dianthus Therapeutics by 3.1% during the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock valued at $313,000 after acquiring an additional 433 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

DNTH has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Guggenheim restated a “buy” rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $54.33.

Dianthus Therapeutics Trading Down 0.7 %

DNTH stock opened at $21.70 on Friday. The company’s 50-day moving average price is $19.86 and its 200 day moving average price is $22.76. Dianthus Therapeutics, Inc. has a 52 week low of $13.37 and a 52 week high of $32.27. The company has a market cap of $697.13 million, a P/E ratio of -8.68 and a beta of 1.62.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.